{"url_path":"/sec/mira/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1904286/0001493152-26-023005-index.html","accession_number":"0001493152-26-023005","cik":"0001904286","ticker":"MIRA","issuer_name":"MIRA PHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1904286/0001493152-26-023005-index.html","primary_entity_key":"0001904286","primary_entity_name":"MIRA PHARMACEUTICALS, INC."},"word_count":680,"has_tables":true,"body_markdown":"false\nQ1\n--12-31\n0001904286\n\n0001904286\n\n2026-01-01\n2026-03-31\n\n0001904286\n\n2026-05-14\n\n0001904286\n\n2026-03-31\n\n0001904286\n\n2025-12-31\n\n0001904286\n\nus-gaap:RelatedPartyMember\n\n2026-03-31\n\n0001904286\n\nus-gaap:RelatedPartyMember\n\n2025-12-31\n\n0001904286\n\n2025-01-01\n2025-03-31\n\n0001904286\n\nus-gaap:CommonStockMember\n\n2024-12-31\n\n0001904286\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2024-12-31\n\n0001904286\n\nus-gaap:RetainedEarningsMember\n\n2024-12-31\n\n0001904286\n\n2024-12-31\n\n0001904286\n\nus-gaap:CommonStockMember\n\n2025-12-31\n\n0001904286\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-12-31\n\n0001904286\n\nus-gaap:RetainedEarningsMember\n\n2025-12-31\n\n0001904286\n\nus-gaap:CommonStockMember\n\n2025-01-01\n2025-03-31\n\n0001904286\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-01-01\n2025-03-31\n\n0001904286\n\nus-gaap:RetainedEarningsMember\n\n2025-01-01\n2025-03-31\n\n0001904286\n\nus-gaap:CommonStockMember\n\n2026-01-01\n2026-03-31\n\n0001904286\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-01-01\n2026-03-31\n\n0001904286\n\nus-gaap:RetainedEarningsMember\n\n2026-01-01\n2026-03-31\n\n0001904286\n\nus-gaap:CommonStockMember\n\n2025-03-31\n\n0001904286\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-03-31\n\n0001904286\n\nus-gaap:RetainedEarningsMember\n\n2025-03-31\n\n0001904286\n\n2025-03-31\n\n0001904286\n\nus-gaap:CommonStockMember\n\n2026-03-31\n\n0001904286\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-03-31\n\n0001904286\n\nus-gaap:RetainedEarningsMember\n\n2026-03-31\n\n0001904286\n\nMIRA:StockOptionsMember\n\n2026-01-01\n2026-03-31\n\n0001904286\n\nMIRA:StockOptionsMember\n\n2025-01-01\n2025-03-31\n\n0001904286\n\nMIRA:CommonStockWarrantsMember\n\n2026-01-01\n2026-03-31\n\n0001904286\n\nMIRA:CommonStockWarrantsMember\n\n2025-01-01\n2025-03-31\n\n0001904286\n\nMIRA:MiralogxllcMember\nMIRA:LicenseAgreementMember\n\n2026-01-01\n2026-03-31\n\n0001904286\n\nMIRA:MiralogxllcMember\nMIRA:LicenseAgreementMember\nMIRA:CommonStockPurchaseWarrantMember\n\n2023-11-15\n2023-11-15\n\n0001904286\n\nMIRA:MiralogxllcMember\nMIRA:LicenseAgreementMember\nMIRA:CommonStockPurchaseWarrantMember\n\n2023-11-15\n\n0001904286\n\nMIRA:MiralogxllcMember\nsrt:MinimumMember\nMIRA:LicenseAgreementMember\n\n2023-11-05\n\n0001904286\n\nMIRA:MiralogxllcMember\nMIRA:LicenseAgreementMember\nsrt:MinimumMember\n\n2023-11-15\n2023-11-15\n\n0001904286\n\nMIRA:TelomirPharmaceuticalsIncMember\n\n2025-09-29\n2025-09-29\n\n0001904286\n\nMIRA:TelomirPharmaceuticalsIncMember\n\n2025-09-29\n\n0001904286\n\nMIRA:SKNYPharmaceuticalsIncMember\n\n2025-09-29\n2025-09-29\n\n0001904286\n\nMIRA:SKNYPharmaceuticalsIncMember\n\n2025-09-29\n\n0001904286\n\nMIRA:TelomirPharmaceuticalsIncMember\n\n2026-03-31\n\n0001904286\n\nMIRA:UndesignatedPreferredStockMember\n\n2026-03-31\n\n0001904286\n\nMIRA:ATMAgreementMember\nus-gaap:CommonStockMember\n\n2024-08-12\n2024-08-12\n\n0001904286\n\nMIRA:ATMAgreementMember\nus-gaap:CommonStockMember\n\n2024-09-24\n2024-09-24\n\n0001904286\n\nMIRA:ATMAgreementMember\nus-gaap:CommonStockMember\n\n2025-01-01\n2025-03-31\n\n0001904286\n\nMIRA:ATMAgreementMember\nus-gaap:CommonStockMember\n\n2025-03-31\n\n0001904286\n\nus-gaap:RestrictedStockUnitsRSUMember\n\n2026-03-29\n2026-03-29\n\n0001904286\n\nsrt:MinimumMember\n\n2025-09-11\n\n0001904286\n\nsrt:MaximumMember\n\n2025-09-11\n\n0001904286\n\n2022-06-30\n\n0001904286\n\nMIRA:TwoThousandAndTwentyTwoOmnibusPlanMember\n\n2026-03-31\n\n0001904286\n\nsrt:MaximumMember\n\n2025-03-26\n2025-03-26\n\n0001904286\n\n2026-03-29\n\n0001904286\n\n2026-03-29\n2026-03-29\n\n0001904286\n\nus-gaap:EmployeeStockOptionMember\n\n2025-12-31\n\n0001904286\n\nus-gaap:EmployeeStockOptionMember\n\n2025-01-01\n2025-12-31\n\n0001904286\n\nus-gaap:EmployeeStockOptionMember\n\n2026-01-01\n2026-03-31\n\n0001904286\n\nus-gaap:EmployeeStockOptionMember\n\n2026-03-31\n\n0001904286\n\nus-gaap:RestrictedStockUnitsRSUMember\n\n2025-12-31\n\n0001904286\n\nus-gaap:RestrictedStockUnitsRSUMember\n\n2026-01-01\n2026-03-31\n\n0001904286\n\nus-gaap:RestrictedStockUnitsRSUMember\n\n2026-03-31\n\n0001904286\n\nus-gaap:WarrantMember\n\n2025-12-31\n\n0001904286\n\nus-gaap:WarrantMember\n\n2025-01-01\n2025-12-31\n\n0001904286\n\nus-gaap:WarrantMember\n\n2026-01-01\n2026-03-31\n\n0001904286\n\nus-gaap:WarrantMember\n\n2026-03-31\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\nxbrli:pure\n\nutr:sqft\n\n \n\n \n\n \n\n**UNITED\nSTATES**\n\n**SECURITIES\nAND EXCHANGE COMMISSION**\n\n**Washington,\nD.C. 20549**\n\n \n\n**Form\n10-Q**\n\n \n\n☒\n**QUARTERLY\nREPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**For\nthe quarterly period ended March 31, 2026**\n\n \n\n☐\n**TRANSITION\nREPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**For\nthe transition period from ________to_________**\n\n \n\n**Commission\nfile number 001-41765**\n\n \n\n**MIRA\nPharmaceuticals, Inc.**\n\n**(Exact\nname of registrant as specified in its charter)**\n\n \n\n**Florida**\n \n**85-3354547**\n\n**(State\nor other jurisdiction of**\n\n**incorporation\nor organization)**\n\n \n\n**(I.R.S.\nEmployer**\n\n**Identification\nNo.)**\n\n \n \n \n\n**1200\nBrickell Avenue, Suite 1950 #1183, Miami, Florida**\n \n**33131**\n\n**(Address\nof principal executive offices)**\n \n**(Zip\nCode)**\n\n \n\n**Registrant’s\ntelephone number (including area code):**\n\n**(786)****432\n9792**\n\n \n\n**Not Applicable**\n\n**(Former name, former address and former fiscal year,\nif changed since last report)**\n\n \n\n**Securities\nregistered pursuant to Section 12(b) of the Act:**\n\n \n\n**Title\nof each class**\n** **\n**Trading\nSymbol(s)**\n** **\n**Name\nof exchange on which registered**\n\n**Common\nstock, par value $0.0001**\n \n**MIRA**\n \n**The\nNasdaq Capital Market**\n\n \n\nIndicate\nby check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities\nExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such\nreports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒\nNo ☐\n\n \n\nIndicate\nby check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to\nRule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the\nregistrant was required to submit such files). Yes\n☒ No ☐\n\n \n\nIndicate\nby check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting\ncompany or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller\nreporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\n \nLarge\naccelerated filer\n☐\nAccelerated\nfiler\n☐\n\n \nNon-accelerated\nfiler\n☒\nSmaller\nreporting company\n☒\n\n \n \n \nEmerging\ngrowth company\n☒\n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate\nby check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒\n\n \n\nAs\nof May 14, 2026, there were 42,022,087\nshares of the registrant’s common stock, par value $0.0001\nissued and outstanding.\n\n \n\n \n\n \n\n \n\n \n\n \n\n**MIRA\nPharmaceuticals, Inc.**\n\n**Quarterly\nReport on Form 10-Q**\n\n**TABLE\nOF CONTENTS**\n\n \n\n \n \n**Page**\n\n \n \n \n\n[**Part\nI. Financial Information**](#hg_001)\n1"}